SCHEMBL20819791

SCHEMBL20819791

c1ccc2cc(C3=NCCC3)ccc2c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRNB4 P30926 10/20 0.53
CHRNA3 P32297 10/20 0.53
NISCH Q9Y2I1 1/20 0.49
CYP1A2 P05177 3/20 0.47
ALDH1A1 P00352 1/20 0.47
THRB P10828 1/20 0.47
CYP2C19 P33261 1/20 0.47
CHRNA7 P36544 2/20 0.46
GSTP1 P09211 1/20 0.41
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
CYP17A1 P05093 1/20 0.41
CYP19A1 P11511 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
ALOX5 P09917 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL165812 0.76 CHRNB4 (0.87) CHRNB4CHRNA3NISCHCYP1A2ALDH1A1
SCHEMBL12363751 0.74 NPC1 (0.59) CHRNB4CHRNA3CYP1A2ALDH1A1THRB
SCHEMBL14047263 0.72 CHRNB4 (0.54) CHRNB4CHRNA3CYP1A2ALDH1A1THRB
SCHEMBL1977761 0.72 CHRNB4 (0.54) CHRNB4CHRNA3CYP1A2ALDH1A1THRB
SCHEMBL31578497 0.71 MAOA (0.43) NISCHCYP1A2ALDH1A1GSTP1ESR1
SCHEMBL19844058 0.71 NISCH (0.43) NISCHCYP1A2GSTP1ESR1ESR2
SCHEMBL28652255 0.71 NQO1 (0.42) NISCHCYP1A2ALDH1A1CYP2C19GSTP1
SCHEMBL6558703 0.70 CHRNB4 (0.90) CHRNB4CHRNA3NISCHCYP1A2ALDH1A1
SCHEMBL433117 0.70 CHRNB4 (0.90) CHRNB4CHRNA3NISCHCYP1A2ALDH1A1
SCHEMBL6796957 0.70 CHRNA7 (0.54) CHRNB4CHRNA3NISCHCYP1A2CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109988091-B Preparation method of imine compound 苏州大学 2022-03-18 CN disclosed
US-11161863-B2 Chiral catalyst and method for asymmetric reduction of an imine DALHOUSIE UNIVERSITY (CA) 2021-11-02 US disclosed
US-11161863-B2 Chiral catalyst and method for asymmetric reduction of an imine DALHOUSIE UNIVERSITY (CA) 2021-11-02 US disclosed
US-20200255463-A1 CHIRAL CATALYST AND METHOD FOR ASYMMETRIC REDUCTION OF AN IMINE DALHOUSIE UNIVERSITY (CA) 2020-08-13 US disclosed
US-20200255463-A1 CHIRAL CATALYST AND METHOD FOR ASYMMETRIC REDUCTION OF AN IMINE DALHOUSIE UNIVERSITY (CA) 2020-08-13 US disclosed
WO-2019051585-A1 CHIRAL CATALYST AND METHOD FOR ASYMMETRIC REDUCTION OF AN IMINE DALHOUSIE UNIVERSITY (CA) 2019-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255463-A1 CHIRAL CATALYST AND METHOD FOR ASYMMETRIC REDUCTION OF AN IMINE C1R, C5, C1S CHRNB4 2102/4885CHRNA3 1979/4885NISCH 257/4885
US-11161863-B2 Chiral catalyst and method for asymmetric reduction of an imine C1R, C5, C1S CHRNB4 2102/4885CHRNA3 1979/4885NISCH 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.